|
| |
BioPortfolio's Approved Drugs DatabaseCampathAlemtuzumabDownload PDF containing detailed information.
Press Releases About Campath:
|
 |
| Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight |
5th November, 2009 |
Reportlinker |
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report |
24th September, 2009 |
Reportlinker |
-- SERMS
The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type
|
| Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 |
26th May, 2009 |
Decision Resources |
Emerging Novel Oral Therapies Will Garner 29 Percent of the Total Market in 2018, According to a New Report from Decision Resources
WALTHAM, Mass., May 26 /PRNewswire/ -- Decision Resources, one of
|
| GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL |
20th January, 2009 |
Decision Resources |
An Agent Showing Improvement in Overall Response Rate Would Earn Higher Patient Share in U.S. Than Europe, According to a New Report from Decision Resources
WALTHAM, Mass., Jan. 20 /PRNewswire/ --
|
Companies working in the area of Campath from Bioportfolio's Biocorporate database : | |
| Company Name | |
Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ILEX is also advancing a robust pipeline of oncology product...
www.ilexonc.com/ View full profile
| |
LeukoSite is a leader in the discovery and development of therapeutics based upon the biology of leukocytes. Therapeutics developed using LeukoSite technology may be used to treat cancer and...
www.kospharm.com/ View full profile
| |
This page has been viewed 31 times
Recent Search Terms used to find this page: treatments market share campath | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Campath across BioPortfolio, or for Campath Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
